The Cartherics allogeneic (off-the-shelf) technology is based on umbilical cord blood cells from rare histocompatibility donors that are converted to stem cells (iPSCs) and gene edited to introduce CARs and to knock-out genes that inhibit immune function. The products are complex versions of the patient’s immune cells altered to aggressively attack solid tumours and endometriosis. EVs are extracted from the manufacturing media and used to modify the tumour microenvironment, this may enable unfretted immune attack by the CAR-immune cells and free the patient’s own immune cells to be recruited for cancer control. EVs may be used as follow-up therapy for cancer and endometriosis as an inhaled product.